Particulate Form (e.g., Powders, Granules, Beads, Microcapsules, And Pellets) Patents (Class 424/489)
  • Patent number: 10307371
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 4, 2019
    Assignee: AI Therapeutics, Inc.
    Inventors: Thomas Armer, Lawrence S. Melvin, Jr., Jonathan M. Rothberg, Henri Lichenstein
  • Patent number: 10307370
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: June 4, 2019
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Thomas Armer, Lawrence S. Melvin, Jr.
  • Patent number: 10307372
    Abstract: Non-adhesive particles as large as 110 nm can diffuse rapidly in the brain ECS, if coated with hydrophilic coatings such as PEG coatings and preferably having neutral surface charge. The ability to achieve brain penetration with larger particles will significantly improve drug and gene delivery within the CNS since larger particles offer higher drug payload, improved drug loading efficiency, and significantly longer drug release durations.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: June 4, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Justin Hanes, Graeme F. Woodworth, Elizabeth A. Nance
  • Patent number: 10307431
    Abstract: An improved lyophilized cyclophosphamide solid composition is described. The lyophilized cyclophosphamide solid composition is thermally stable, contains anhydrous cyclophosphamide and mannitol, and is substantially free of cyclophosphamide monohydrate. A method for preparing the lyophilized cyclophosphamide solid composition is also provided.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: June 4, 2019
    Assignee: AMPAC Fine Chemicals LLC
    Inventors: Andrew M. Smith, Timothy S. Dutill, Edward H. Trappler
  • Patent number: 10301332
    Abstract: Provided is a method of controlling release of nitric oxide, and more particularly, to a method of selectively releasing nitric oxide depending on a change in pH using calcium phosphate. The method of selectively releasing nitric oxide according to the present invention may stably deliver nitric oxide to a desired site, and induce release of nitric oxide by a change in pH, thereby making it possible to improve a therapeutic effect while preventing a loss of nitric oxide.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: May 28, 2019
    Assignees: Institute for Basic Science, Postech Academy-Industry Foundation
    Inventors: Won Jong Kim, Jihoon Kim, Hyung Woo Choi
  • Patent number: 10300041
    Abstract: Aqueous suspensions for oral administration are disclosed that include simvastatin having a d90 of simvastatin particles of less than about 100 ?m as the active agent. The aqueous suspension also includes simvastatin as about 20 mg to about 80 mg per 5 ml of the aqueous suspension, a suspending agent as about 20 mg to about 50 mg of the aqueous suspension, a wetting agent, an antimicrobial preservative, an antifoaming agent, water, and a buffering system providing the aqueous suspension with a pH of about 6.4 to about 7. Methods of making such a suspension and methods of treatments in orally administering the same are also disclosed.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: May 28, 2019
    Assignee: Rosemont Pharmaceuticals LTD
    Inventor: Phillip Driver
  • Patent number: 10292932
    Abstract: Disclosed are an anionic drug-containing polymeric micelle particle comprising: an anionic drug as an active ingredient; a cationic lipid; and an amphiphilic block copolymer, wherein the anionic drug forms a complex with the cationic lipid, and the complex is entrapped in the micelle structure of the amphiphilic block copolymer, and a method for preparing the same. The particle may increase stability of the anionic drug in blood or in a body fluid, and it may enable intracellular delivery to improve efficacy of anionic drugs.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: May 21, 2019
    Assignee: SAMYANG BIOPHARMACEUTICALS CORPORATION
    Inventors: Se-Ho Kim, Ji-Yeon Son, Muhn-Ho La, Sung-Won Choi, Min-Hyo Seo
  • Patent number: 10286073
    Abstract: This disclosure describes a composition and method of magnetic nanoparticles (MNP) that are bound to a baculovirus (BV). The MNP-BV can be systemically administered to a patient, and a strong magnetic field applied to the target tissue, thus allowing uptake and expression only in the target tissue. Off-target effects are not seen because the MNP-BC is inactivated by the complement system outside of the magnetic field.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: May 14, 2019
    Assignee: ILISA TECH, INC.
    Inventors: Haibao Zhu, Sheng Tong, Gang Bao
  • Patent number: 10280737
    Abstract: Carbon quantum dots are used as tracers during the production of hydrocarbons. The tracer may be used to identify fluids produced from the reservoir. When used in the fracturing of multiple zones of the reservoir, qualitatively distinguishable carbon quantum dots may be used to identify the zone within the reservoir from which recovered fluid was produced. The carbon quantum dots may also be used in water flooding to determine water breakthrough in the production well. Upon water breakthrough in a production well, they may also be used to identify those injection wells from which breakthrough water originates.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: May 7, 2019
    Assignee: Baker Hughes, a GE company, LLC
    Inventors: D. V. Satyanarayana Gupta, Sankaran Murugesan, Oleksandr Kuznetsov, Radhika Suresh, Valery N. Khabasheku
  • Patent number: 10272050
    Abstract: This disclosure relates to nanoparticles, compositions, methods of making, and methods of use thereof.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: April 30, 2019
    Assignees: The Brigham and Women's Hospital, Inc., President and Fellows of Harvard College
    Inventors: Omid C. Farokhzad, Won Il Choi, Ulrich von Andrian, Nazila Kamaly
  • Patent number: 10272019
    Abstract: Core-shell particles have a hydrophobic core and a shell formed of or containing hyperbranched polyglycerol (HPG). The HPG can be covalently bound to the one or more materials that form the core or coated thereon. The HPG coating can be modified to adjust the properties of the particles. For example, unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption. Alternatively, the hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups on tissue or otherwise interact with tissue to adhere the particles to the tissue, cells, or extracellular materials, such as proteins. Such functional groups include, but not limited to, aldehydes, amines, and O-substituted oximes. Topical formulation for application to the skin contain these HPG coated nanoparticles.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: April 30, 2019
    Assignee: Yale University
    Inventors: Yang Deng, Asiri Ediriwickrema, William M. Saltzman
  • Patent number: 10265288
    Abstract: The invention features methods of treating a proliferative disorder characterized by elevated Pin1 marker levels and/or reduced Pin1 Ser71 phosphorylation in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating proliferative disorders (e.g., proliferative disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with another anti-proliferative compound. Finally, the invention also features methods including high-throughput screens for discovering and validating Pin1 inhibitors.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: April 23, 2019
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Shuo Wei, Xiao Zhen Zhou
  • Patent number: 10258941
    Abstract: Disclosed herein are apparatus and methods for producing emulsions, and, in particular, for maintaining laminar flow during production of emulsions containing microsuspensions. Disclosed herein are columns for receiving a packing material that permits fluid flow through the column. The columns have a periphery that defines an interior cavity in fluid communication with inlets and outlets of the column. Disclosed herein is a method of preparing an emulsion that includes (1) forming a first phase typically containing an organic solvent, a polymer, and one or more biologically active agents and/or chemicals; (2) forming a second phase typically containing water as the second solvent, an emulsion stabilizer and optionally a solvent; and (3) passing the first and the second phases through the column to form a “water in oil” type emulsion.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: April 16, 2019
    Assignee: Evonik Corporation
    Inventors: Bruce W. Hudson, Gary W. Opperman, Adrian T. Raiche
  • Patent number: 10261074
    Abstract: Methods, systems, compositions include biocompatible polymer coated nanoceria that function as aqueous redox catalyst with enhanced activity at an acidic to moderately alkaline pH value between 1 and 8. The compositions are used as oxidizing agents for decomposition, decontamination or inactivation of organic contaminants, such as, pesticides and chemical warfare agents. Another use includes nanoceria as targetable nanocatalyst prepared by conjugating various targeting ligands to the nanoparticle coating to form a colorimetric or fluorescent probe in immunoassays and other molecule binding assays that involve the use of a molecule in solution that changes the color of the solution or emits a fluorescent signal, where localization of nanoceria to organs or tissue is assessed by treatment with an oxidation sensitive dye or other detection devices.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: April 16, 2019
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Jesus Manuel Perez, Atul Asati, Santimukul Santra, Charalambos Kaittanis, Sudip Nath
  • Patent number: 10251891
    Abstract: A liquid pharmaceutical compositions comprising Aprepitant is preferably prepared as an oral suspension dosage form for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: April 9, 2019
    Assignee: InnoPharma, Inc.
    Inventors: Udaya Toti, Shyamprasad Mukundan, Sasank Chaitanya Kunadharaju, Tushar Hingorani, Kumaresh Soppimath, Satish Pejaver, Navneet Puri
  • Patent number: 10251866
    Abstract: The present invention in general relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one active ingredient and at least one dicarboxylic acid. It in particular relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one anthelmintic drug and at least one dicarboxylic acid. The invention further relates to uses, methods for use and methods for manufacturing the pharmaceutical suspension according to this invention.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: April 9, 2019
    Assignee: Universiteit Gent
    Inventors: Jean Paul Remon, Chris Vervaet
  • Patent number: 10251935
    Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. Such formulations are stable at room temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: April 9, 2019
    Assignee: NoNO Inc.
    Inventor: Jonathan David Garman
  • Patent number: 10245306
    Abstract: A synthetic, flexible tissue matrix and methods for repairing hyaline cartilage defects in a joint using the flexible tissue matrix are described. The flexible tissue matrix includes a high molecular weight polycaprolactone polymer entangled with a polysaccharide such as hyaluronic acid. In the methods, autologous bone mesenchymal stem cells are introduced to a joint by a microfracturing technique, and a membrane made of the flexible matrix is applied to the joint. Cartilage which forms in the joint is hyaline cartilage rather than fibrocartilage.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 2, 2019
    Assignee: ISTO TECHNOLOGIES II, LLC
    Inventors: Mitchell S. Seyedin, Anthony J. Ward, Matthew Matava
  • Patent number: 10238688
    Abstract: The disclosure provides drug combinations and methods for treating human bladder cancer. The drug combination may include mitomycin, or an analog thereof, cisplatin or an alternative platinum drug, and epirubicin or an alternative anthracycline drug and does not include gemcitabine.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: March 26, 2019
    Assignee: Genedia Biotech Co., Ltd.
    Inventor: Jingde Zhu
  • Patent number: 10238601
    Abstract: The invention provides a method of making a composition for inhalation which includes the step of mixing particles of additive material having a diameter of not more than 2 ?m with active particles, wherein the additive material is suitable for promoting the dispersal of active particles upon aerolisation of a dry powder in a dry powder inhaler.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: March 26, 2019
    Assignee: VECTURA LIMITED
    Inventors: John Nicholas Staniforth, David Alexander Vodden Morton
  • Patent number: 10238581
    Abstract: Core-shell particles and methods of making and using thereof are described herein. The core is formed of or contains one or more hydrophobic materials or more hydrophobic materials. The shell is formed of or contains hyperbranched polyglycerol (HPG). The HPG coating can be modified to adjust the properties of the particles. Unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption and increase circulation in the blood. The hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups and adhere the particles to tissue, cells, or extracellular materials, such as proteins.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: March 26, 2019
    Assignee: Yale University
    Inventors: Yang Deng, Asiri Ediriwickrema, William M. Saltzman
  • Patent number: 10227718
    Abstract: Continuous processing methods for making absorbable polymeric dry spun non-wovens with one or more of the following properties: high burst strength, fine fibers of average diameter from 0.01 ?m to 50 ?m, and thickness from 10 ?m to 10 mm, have been developed. Improved fiber cohesion is made possible by controlling the tackiness of the fibers of the non-woven during web collection. The polymer is preferably a polyhydroxyalkanoate, more preferably, a 4-hydroxybutyrate polymer or copolymer. A non-woven of poly-4-hydroxybutyrate is most preferred. The non-wovens have fine fibers with average diameters ranging from 0.01 ?m to 50 ?m, and are derived by dry spun processing, during which a solution of polymer(s) is injected into a stream of high velocity air with a pressure of 1 to 500 psi for solvent stripping and polymer strand attenuation. The non-wovens can be used for a variety of purposes including fabrication of medical devices.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: March 12, 2019
    Assignee: Tepha, Inc.
    Inventors: Ryan Cahil, Kai Guo, David P. Martin, Said Rizk, Kicherl Ho, Simon F. Williams
  • Patent number: 10226049
    Abstract: An insecticidal granular composition for broadcasting of the granular composition onto a body of water on which insects are to be controlled comprising: a granular carrier of size in range of from 1 to 4 mm; a composition absorbed into the granular carrier comprising a bacterially derived larvicidal active agent and a non-aqueous liquid having a density less than 1; wherein the insecticidal granular composition has an average individual granule density greater than 1 and is adapted to sink in the body of water.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: March 12, 2019
    Assignee: Granular Products Assets PTY LTD
    Inventors: Graham Barrett, Philip Pentland, Abhinetiri Kumari Maharaj
  • Patent number: 10213458
    Abstract: Differential surface-charge-dependent localization of nanoceria in normal cells and cancer cells plays a critical role in the toxicity profile of a nanoceria particle. Engineered surface-coated cerium oxide nanoparticles with different surface charges that are positive, negative and neutral provide therapeutic results for normal and cancer cell lines. Results show that nanoceria with a positive or neutral charge enters most of the cell lines studied, while nanoceria with a negative charge internalizes mostly in the cancer cell lines. Moreover, upon entry into the cells, nanoceria is localized to different cell compartments (e.g. cytoplasm and lysosomes) depending on the nanoparticle surface charge. The internalization and subcellular localization of nanoceria plays a key role in the nanoparticle cytotoxicity profile, exhibiting significant toxicity when they localize in the lysosomes of the cancer cell lines.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: February 26, 2019
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Jesus Manuel Perez, Atul Asati, Santimukul Santra, Charalambos Kaittanis
  • Patent number: 10206973
    Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c, as chloride salts. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. The chloride salt of TAT-NR2B9c shows improved stability compared with the acetate salt form of prior formulations. Formulations of the chloride salt of TAT-NR2B9c are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: February 19, 2019
    Assignee: NoNO INC.
    Inventor: Jonathan David Garman
  • Patent number: 10206417
    Abstract: The guava seed (Psidium guajava) nanoparticles as an antibacterial agent are prepared from guava seeds that have been washed, dried, and ground to powder of less than 1 mm diameter. The powder is reduced to nanoparticle size (less than 100 nm diameter) by adding the powder to a solution of concentrated hydrochloric acid (38% w/w) and stirring the mixture at 3000 rpm at room temperature. The resulting nanoparticles are filtered through a Millipore membrane filter and dried. Agar well diffusion studies showed significant antibacterial activity against various Gram positive and negative species commonly implicated in food contamination. Further testing showed the guava seed nanoparticles have significant antioxidant and radical scavenging content, suggesting that guava seed nanoparticles may serve as an antibacterial agent.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: February 19, 2019
    Assignee: King Saud University
    Inventors: Hatem Salama Mohamed Ali, Reem Atta Alajmi, Hany Mohamed Yehia, Mohamed Fekry Serag El-Din, Manal Fawzy Elkhadragy, Manal Ahmed Gasmelseed Awad, Dina Mahmoud Metwally Hasanin
  • Patent number: 10201573
    Abstract: Methods of treating vascular damage caused by a cerebral vascular accident in a subject are provided. The method includes the step of administering an effective amount of a human birth tissue material composition to a damaged site in a brain.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: February 12, 2019
    Assignee: Brahm Holdings, LLC
    Inventor: Timothy R. Brahm
  • Patent number: 10189957
    Abstract: A method for preparing solid materials is described. One aspect of the method includes the steps of (a) providing a feedstock comprising an organic material(s) in a solvent system containing a non-solvent for the organic material at an elevated temperature and/or pressure above ambient conditions, (b) distributing the feedstock into either droplets or a film, and (d) evaporating the solvent system from the feedstock.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: January 29, 2019
    Assignee: ISP INVESTMENTS LLC
    Inventors: Albert W. Brzeczko, John A. Doney
  • Patent number: 10188646
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: January 29, 2019
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Bronislava Gedulin, Andrew A. Young, Howard E. Greene
  • Patent number: 10183926
    Abstract: The present invention relates to a pseudo-ceramide compound and a method for preparing the same. The pseudo-ceramide compound of the present invention may provide antioxidant effects, and exhibits improved properties such as high solubility compared to existing natural ceramides and pseudo-ceramide compounds, and therefore, may be included in large quantities in the formulation. Accordingly, the pseudo-ceramide compound may be used in various fields such as cosmetics, medicinal substances, external preparations and foods.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: January 22, 2019
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Yung Hyup Joo, Jae Won Yoo, Yong Jin Kim, Ho Sik Rho, John Hwan Lee
  • Patent number: 10183068
    Abstract: This disclosure describes, generally, compositions and methods related to thermostable vaccine formulations, their storage, and their use. Generally, the thermostable vaccine formulations can be in the form of a dry powder. The dry powder formulations can increase the length of time that the vaccine remains viable under non-refrigerated, ambient temperature conditions.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: January 22, 2019
    Inventors: Pavan Muttil, Denis Wafula, Terry Wu, Nitesh Kunda, Dominique N. Price
  • Patent number: 10179107
    Abstract: The present invention relates to a tablet having a weight of 30-200 mg and consisting of: 60-100 wt. % of granules consisting of: 50-90% by weight of the granules of dehydroepiandrosterone (DHEA); 6-35% by weight of the granules of microcrystalline cellulose; 0-20% by weight of the granules of one or more other pharmaceutically acceptable granule ingredients; and 0-40 wt. % of one or more other pharmaceutically acceptable tablet components. These tablets can suitably be used to orally administer DHEA in dosages of around 50 mg and are sufficiently small to be incorporated in, for instance, ordinary oral contraceptive blister packs.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: January 15, 2019
    Assignee: PANTARHEI BIOSCIENCE B.V.
    Inventors: Herman Jan Tijmen Coelingh Bennink, Johannes Jan Platteeuw
  • Patent number: 10172804
    Abstract: The present invention is directed to a composition comprising particles of pimobendan with an integral coating of a carrier matrix which serve to ensure a rapid dissolution of the active substance at each pH condition representing the gastrointestinal tract and therefore a reliable absorption, and a method of pimobendan microencapsulation using the spray congealing technology and incorporating the coated particles into oral formulations, for example into tablets.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: January 8, 2019
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventor: Péter Laczay
  • Patent number: 10159642
    Abstract: The purpose of the present invention is to provide: a functional polymer gel which is able to be practically used as an ocular lens having excellent transparency and mechanical strength by uniformly dispersing organic nanotubes in a polymer gel without the formation of agglomerates of the organic nanotubes in the case where the organic nanotubes are complexed into the polymer gel; and a method for producing this functional polymer gel. The above-mentioned purpose is achieved by: a functional polymer gel which is characterized by containing organic nanotubes and having a light transmittance of 80% or more; and a method for producing this functional polymer gel.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: December 25, 2018
    Assignees: SEED CO., LTD., NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Yoshiko Yamazaki, Takao Sato, Wuxiao Ding, Mitsutoshi Masuda, Momoyo Wada
  • Patent number: 10159671
    Abstract: Described herein is a composition comprising: (a) a first population of particles of a first aripiprazole prodrug; and (b) a second population of particles of a second aripiprazole prodrug, different to the first aripiprazole prodrug. At least one of the first and second prodrug populations has a volume based particle size (Dv50) of less than about 1000 nm. Also described herein are methods of treatment using the aforementioned composition, and methods of making the aforementioned composition.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: December 25, 2018
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Tarek A. Zeidan, David Manser, Kristopher Perkin, Philip Cresswell, Magali Hickey, Brian Steinberg
  • Patent number: 10159656
    Abstract: The invention provides compositions including epinephrine fine particles, including epinephrine nanoparticles or nanocrystals and epinephrine microparticles or microcrystals, and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine fine particles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 25, 2018
    Assignee: NOVA SOUTHEASTERN UNIVERSITY
    Inventors: Mutasem Rawas-Qalaji, Ousama Rachid, Keith Simons, Estelle Simons
  • Patent number: 10155064
    Abstract: Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: December 18, 2018
    Assignee: MicroVention, Inc.
    Inventors: Gregory M. Cruise, Steve Plotkin, Xinping Wu
  • Patent number: 10149879
    Abstract: Provided herein are plant based formulations for the prevention and management of diabetic vascular complication The formulation include hydro-alcoholic extract of Berberis Aristata, Trigonella foenum-graceum and Salacia parviflora in an effective dose. Also provided herein are methods of using such formulations.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: December 11, 2018
    Inventors: Harinder Singh Gill, Gurpreet Singh Gill
  • Patent number: 10150877
    Abstract: According to the invention, an electrophoretic dispersion liquid includes at least one type of an electrophoretic particle, and a dispersion medium, in which the content of transition metal of group 8 elements derived from a catalyst which is used to generate at least one of a block copolymer (a particle surface treatment agent) used to form the electrophoretic particle and the dispersion medium is in a range of greater than 0 ppm to equal to or less than 2 ppm in the electrophoretic dispersion liquid.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: December 11, 2018
    Assignee: E Ink Corporation
    Inventors: Harunobu Komatsu, Masahiko Nakazawa, Kiyoshi Nakamura, Hiroki Nakahara
  • Patent number: 10143754
    Abstract: A method for treating type 1 and type 2 diabetes by administering an oral pharmaceutical formulation which comprises of insulin or its analogs amalgamated with suitable encapsulating agents and pharmaceutical excipients. The encapsulated pharmaceutical oral formulation protects insulin or its analogs from harsh milieu of the gastrointestinal tract and facilitates efficient delivery of insulin at targeted sites with sustained hypoglycemic activity.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: December 4, 2018
    Assignee: TRANSGENE BIOTEK LIMITED
    Inventors: Koteswara Rao Kollipara, Gregory John Russell Jones
  • Patent number: 10143651
    Abstract: The present application relates to a micelle comprising a drug encapsulated by an amphiphilic polymer and a composition comprising the same. The micelle of the present application has an excellent dispersion property on an aqueous solution and a superior percutaneous absorption characteristic on preparing a formulation.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: December 4, 2018
    Assignees: LG Chem, Ltd., LG Household & Health Care Ltd.
    Inventors: Su Jeong Kim, Jeong Ae Yoon, Sun Hwa Lee, Woo Sun Shim, Sung Soo Yoon, Chang Hwan Ju, Jung A Kim, Nae Gyu Kang
  • Patent number: 10137126
    Abstract: A method of preparing a very slightly soluble drug with solid composition includes the following steps: (a) adding a very slightly soluble drug into an organic solvent and polysorbate to form a first solution; (b) adding the first solution into a second solution and a pharmaceutically acceptable excipient, wherein the second solution comprises water or SLS, and a volume ratio of the first solution and the second solution is between 8:1 and 1:1; and (c) drying and compressing the mixture in step (b) to form a very slightly soluble drug with solid composition.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: November 27, 2018
    Assignee: YUNG SHIN PHARM. IND. CO., LTD.
    Inventors: Fang-Yu Lee, Fu-Yung Lin
  • Patent number: 10138171
    Abstract: A method for enhancing or reducing photosynthetic activity, wherein non-toxic pigmented matter is applied to a photosynthetic organism. Depending on the composition of the pigmented matter, the method will have the effect of enhancing, reducing, or inhibiting photosynthetic activity.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: November 27, 2018
    Inventors: Stacie Z. Berg, Jonathan Rydell
  • Patent number: 10130582
    Abstract: The present disclosure relates to pharmaceutically acceptable complex formulae comprising complexes of Abiraterone acetate and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present disclosure have improved physicochemical properties which results in reduced food effect which allows significant dose reduction and the abandoning of the requirement of taking the drug on an empty stomach.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: November 20, 2018
    Assignee: Druggability Technologies IP Holdco Limited
    Inventors: Réka Angi, Tamás Jordán, Orsolya Basa-Dénes, Tamás Solymosi, Zsolt Ötvös, Hristos Glavinas, Genovéva Filipcsei
  • Patent number: 10130686
    Abstract: Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac™ or Nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: November 20, 2018
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Shaker A. Mousa, Paul J. Davis
  • Patent number: 10124072
    Abstract: The disclosure features methods that include: administering to a subject a composition that includes particles, where each one of the particles features at least one targeting group that binds to a structural entity in the subject and at least one reacting group that reacts chemically with a reactive oxygen species in the subject, and where the particle emits luminescence when the reaction occurs; detecting the luminescence emission from the particles; and displaying an image of the subject showing locations of at least some reactive oxygen species in the subject based on the detected luminescence.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: November 13, 2018
    Inventors: Sunetra Ray, Daniel Ansaldi, Rajendra Singh
  • Patent number: 10111957
    Abstract: The invention relates to pharmaceutical powder compositions administered by means of inhalers. More particularly, it relates to pharmaceutical powder compositions having the content uniformity and the desired stability used in inhaler devices.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: October 30, 2018
    Assignee: Arven Ilac Snayi ve Ticaret A.S.
    Inventors: Ümit Cifter, Ali Turkyilmaz, Onur Mutlu
  • Patent number: 10112910
    Abstract: Provided is a method for the synthesis of N-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: October 30, 2018
    Assignee: MannKind Corporation
    Inventors: John J. Stevenson, Destardi Moye-Sherman
  • Patent number: 10105295
    Abstract: A microcapsule suspension for treating a protein-containing surface includes droplets of a dispersed water-immiscible core phase, an aqueous continuous phase, and a wall surrounding each core phase droplet. The wall includes the salt formed from at least one Lewis base reactant and at least one Lewis acid reactant, wherein at least one Lewis base reactant or Lewis acid reactant is amphiphilic and wherein at least one Lewis acid reactant is selected from the group consisting of proteins, protein hydrolysates, charged amino acids, and water-soluble salts of any of these.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: October 23, 2018
    Assignee: Capsulent
    Inventors: Tycho Joseph Speaker, Sidra Lenore Speaker, Talia Kalei Speaker
  • Patent number: 10098967
    Abstract: Disclosed are conjugates of hydrophobic drugs linked to protected or unprotected amino acids or peptides. The disclosed conjugates are amphiphilic and can self assemble into nantubes. Nanotubes comprising the conjugates are also described and can have high loading of the drug and protect it from degradation or elimination. The nanotubes are well suited to deliver hydrophobic and unstable drugs to individuals.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: October 16, 2018
    Assignees: Ohio State Innovation Foundation, Trustees of Boston University
    Inventors: Jonathan R. Parquette, Se Hye Kim, Mark W. Grinstaff, Jonah A. Kaplan